(Q35202958)

English

Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Leonardo Calza

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Roberto Manfredi

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Francesco Chiodo

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

International Journal of Antimicrobial Agents

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

89-99

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nutritional alterations associated with HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma lipids in HIV-infected patients: a prospective study in 95 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in serum lipoprotein pattern induced by acute infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine function in 98 HIV-infected patients: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine disorders in men infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of dyslipidemia in patients with HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

"Buffalo hump" in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Disorders of fat distribution in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

"Buffalo hump" in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight gain associated with protease inhibitor therapy in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of protease inhibitors on weight and body composition in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Marked hypertriglyceridaemia associated with ritonavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nutritional status changes in HIV-infected children receiving combined antiretroviral therapy including protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of protease inhibitor therapy on lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperlipidemia and inhibitors of HIV protease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitochondrial involvement in antiretroviral therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary artery disease and human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe premature coronary artery disease with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Myocardial infarction in HIV-infected men receiving protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular complications associated with use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Triglycerides as a risk factor for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz: shifting the HAART paradigm in adult HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900115-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0924-8579(03)00115-8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35202958&oldid=1948272836"